Teresa Foy, PhD

Immunologist and Biopharmaceutical R&D Leader

---

Teri Foy, PhD, is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in oncology and inflammation. Her work has focused on advancing immune-based therapies from discovery through clinical translation, spanning cancer and autoimmune disease.

Most recently, she served at Bristol Myers Squibb, where she led the Immuno-Oncology and Cell Therapy Thematic Research Center. In this role, she guided early immuno-oncology and cell therapy programs from discovery through human proof of concept, advancing immune-based biologics and cell therapies across hematologic and solid tumors as well as autoimmune disease. She also built and led cross-functional teams and cultivated strong internal and external scientific collaborations to accelerate pipeline development. Prior to BMS, she spent more than five years at Celgene, helping establish the company’s Seattle site and playing a central role in shaping its immuno-oncology strategy and pipeline. Earlier in her career, she held scientific leadership roles at Corixa and GlaxoSmithKline, and served as Chief Scientific Officer at VLST.

Dr. Foy earned her Ph.D. in Immunology from the University of Iowa, an M.S. in Microbiology, and completed a postdoctoral fellowship in Immunology at Dartmouth Medical School. She has an extensive publication record and holds nearly a dozen patents covering novel immune compositions. She currently serves as a Strategic Advisor to the T1D Fund.